AYTU Historical PE Ratio Notes

— Aytu BioPharma (AYTU) is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics and consumer health products, with an emphasis on pediatric and rare diseases. AYTU’s product portfolio includes both prescription medications & branded consumer health supplements, targeting unmet needs in pediatric medicine, attention deficit disorders, and other niche markets. Since AYTU operates in these high-need, specialized segments, its financial performance can be volatile, especially as it incurs significant R&D costs relative to revenue. For investors examining AYTU's historical P/E (price-to-earnings) ratio, it’s important to note that the company has posted frequent net losses, resulting in either a negative or non-applicable P/E for significant periods. When positive earnings occur—potentially due to a new product launch or licensing deal—these events may temporarily drive the P/E ratio down (making shares appear more attractively valued), or sharp reactions in price or earnings can create significant P/E swings. Fluctuations in AYTU's P/E history reflect the challenges of turning R&D investment into sustainable earnings, and investors should focus on understanding the context behind sudden P/E changes—especially whether they stem from recurring operations or one-time events.

On this page we presented the AYTU Historical PE Ratio information for Aytu BioPharma' stock. The average AYTU historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 1.6. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average AYTU historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this AYTU historical PE result, against the recent PE: when this page was posted on 10/5/2026, the most recent closing price for AYTU had been 2.04, and the most recent quarterly earnings result, annualized, was 0.84. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent AYTU PE on 10/5/2026 based on annualized quarterly EPS was 2.4. Based on AYTU's history, that recent PE is elevated relative to the historical average, with the recent PE 50.0% higher than the historical average PE across our data set for Aytu BioPharma.

For self directed investors doing their due diligence on AYTU or any other given stock, valuation analysis for AYTU can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Aytu BioPharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for AYTU. Thanks for visiting, and the next time you need to research AYTU Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.